Venmax Drugs & Pharmaceuticals Ltd confirmed that all five resolutions proposed at its Thirty Seventh Annual General Meeting (AGM) were passed with the requisite majority. The scrutinizer’s report, dated September 28, 2026, validated the e-voting results from the meeting held on September 26, 2026.

The company submitted the Consolidated Scrutinizer Report and voting results to the Bombay Stock Exchange (BSE) following the conclusion of the remote e-voting process. The resolutions covered the adoption of FY26 financial statements, director reappointments, and changes in director designations.

Voting results breakdown

Shareholders voted via remote e-voting, which remained open from September 23 to September 25, 2026. A total of 92 members participated, casting votes on 64,45,797 valid votes. Across all five agenda items, approximately 95.73% of valid votes were cast in favour, while 4.27% were against. No invalid votes were recorded.

Key resolutions adopted

The adopted resolutions included the standalone audited financial statements for FY26 and several governance-related appointments:

1. Adoption of audited standalone financial statements for FY26.
2. Reappointment of Swapneswar Mishra as Director (retiring by rotation).
3. Change of designation for Venkata Rao Sadhanala to Managing Director.
4. Regularization of Padmaja Kalyani Sadhanala as Non-Executive Non-Independent Director.
5. Regularization of Revoor Ramachandra as Non-Executive Independent Director.

Merger update and strategic context

During the AGM, the Chairman reiterated that the application for the merger of Hatri Pharma Private Limited into Venmax Drugs is subject to the necessary approvals of the Hon’ble National Company Law Tribunal, Hyderabad Bench‑II. The scheme aims to unify business operations, improve resource utilization, and enhance operational efficiency.

This follows the NCLT order dated September 7, 2026, which directed the convening of a separate meeting to approve the Scheme of Arrangement. That specific merger approval meeting is set for October 24, 2026, at 12:30 pm (IST).

Meeting logistics and attendance

The AGM commenced at 12:30 pm and concluded at 12:56 pm. Forty-five members attended through video conferencing. The company engaged Central Depository Services Limited (CDSL) for remote e-voting, with Kashinath Sahu serving as the Scrutinizer. The scrutinizer unblocked the votes on September 26, 2026, at 1:10 pm, in the presence of two witnesses not employed by the company.

Venmax Drugs & Pharmaceuticals has been directed by the National Company Law Tribunal to convene an equity shareholder meeting regarding its proposed amalgamation with Hatri Pharma Private Limited. The tribunal issued the order on September 7, 2026, setting the stage for the next procedural step in the corporate restructuring process.

The National Company Law Tribunal, Hyderabad Bench, scheduled the meeting for Saturday, October 24, 2026, at 12:30 p.m. The session will be conducted through video conference or other audio-visual means, ensuring remote accessibility for shareholders. This directive follows the disposal of Case Application CA (CAA) 30/230/HDB/2026, which was heard before Judicial Member Rajeev Bhardwaj and Technical Member Sanjay Puri.

Scheme Details

The amalgamation falls under sections 230 to 232 of the Companies Act, 2013. Hatri Pharma Private Limited is designated as the amalgamating company, while Venmax Drugs serves as the amalgamated company. The tribunal’s order allows and disposes of the case application, mandating the convening of the shareholder meeting as a critical compliance step.

Venmax Drugs disclosed this development to the BSE Limited on September 8, 2026, citing SEBI Listing Obligations and Disclosure Requirements Regulations, 2015. The company confirmed that the order copy and related documents are available on its official website for stakeholder reference.

What the Numbers Show

While no financial figures were disclosed in this specific regulatory filing, the progression to a shareholder vote indicates regulatory approval of the scheme’s structural validity. The timeline sets a clear deadline for investor engagement, with the October 24 meeting serving as the final approval gate before implementation.